Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company’s subscriber base reached 2.2 million ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ plan to combine all its dermatology services into one main ...

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

Shares of HIMS stock opened at $36.01 on Thursday. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to ...

Bank of New York Mellon Corp grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 128.7% in the fourth quarter, HoldingsChannel reports.The institutional investor owned ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to "simplify its ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to "simplify its (company's ...

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against the other skincare stocks. According to NielsenIQ, the global beauty market is expected to ...